Jounce Therapeutics (JNCE) to Be Acquired by Concentra Biosciences for $1.85 in Cash per Share Plus Contingent Value Rights Mar 27, 2023 09:01AM
Jounce Therapeutics Enters Into Agreement to Be Acquired by Concentra Biosciences for $1.85 in Cash per Share Plus Contingent Value Rights Mar 27, 2023 09:00AM
Raymond James Downgrades Jounce Therapeutics (JNCE) to Market Perform, 'It’s over for our constructive thesis on JTX-8064' Feb 23, 2023 03:49AM
Jounce Therapeutics (JNCE) to cut 57% of workforce Feb 22, 2023 05:13PM
Jounce Therapeutics Announces Restructuring Feb 22, 2023 05:00PM